Gut

Article	Citations
Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19	850
Gut microbiome and health: mechanistic insights	832
Mucus barrier, mucins and gut microbiota: the expected slimy partners?	773
Gut microbiota-derived metabolites as central regulators in metabolic disorders	568
Management ofHelicobacter pyloriinfection: the Maastricht VI/Florence consensus report	474
Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN	448
Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites	433
Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort	321
Gut microbiota dynamics in a prospective cohort of patients with post-acute COVID-19 syndrome	312
Gut microbiome stability and resilience: elucidating the response to perturbations in order to modulate gut health	301
Long-term dietary patterns are associated with pro-inflammatory and anti-inflammatory features of the gut microbiome	270
MicroRNAs as regulators, biomarkers and therapeutic targets in liver diseases	265
Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensus	255
Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals	249
British Society of Gastroenterology guidelines on the management of irritable bowel syndrome	233
Effect of IBD medications on COVID-19 outcomes: results from an international registry	224
Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis	210
Ginseng polysaccharides alter the gut microbiota and kynurenine/tryptophan ratio, potentiating the antitumour effect of antiprogrammed cell death 1/programmed cell death ligand 1 (anti-PD-1/PD-L1) imm	205
The role of gut microbiota in cancer treatment: friend or foe?	204
Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD	204
Depicting SARS-CoV-2 faecal viral activity in association with gut microbiota composition in patients with COVID-19	199
Calprotectin: from biomarker to biological function	196
Impact of the COVID-19 pandemic on UK endoscopic activity and cancer detection: a National Endoscopy Database Analysis	193
Guidelines on the management of ascites in cirrhosis	183
Helicobacter pyloriresistance to antibiotics in Europe in 2018 and its relationship to antibiotic consumption in the community	175

Faecal microbiota transplantation halts progression of human new-onset type 1 diabetes in a randomised controlled trial	173
Alterations in the human oral and gut microbiomes and lipidomics in COVID-19	171
SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting	168
Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis	165
Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching	160
Comparison of mortality risk in patients with cirrhosis and COVID-19 compared with patients with cirrhosis alone and COVID-19 alone: multicentre matched cohort	153
Image-based consensus molecular subtype (imCMS) classification of colorectal cancer using deep learning	153
Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups	153
European Registry on Helicobacter pylori management (Hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients	149
Gut microbiota regulate Alzheimer’s disease pathologies and cognitive disorders via PUFA-associated neuroinflammation	148
Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab	146
Gut microbiota modulates COPD pathogenesis: role of anti-inflammatory Parabacteroides goldsteinii lipopolysaccharide	144
Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies	141
Rapid gut dysbiosis induced by stroke exacerbates brain infarction in turn	139
Effect of green-Mediterranean diet on intrahepatic fat: the DIRECT PLUS randomised controlled trial	137
Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease	135
F. nucleatum targets lncRNA ENO1-IT1 to promote glycolysis and oncogenesis in colorectal cancer	134
Diet quality and risk and severity of COVID-19: a prospective cohort study	132
Six-month follow-up of gut microbiota richness in patients with COVID-19	127
Efficacy of a low FODMAP diet in irritable bowel syndrome: systematic review and network meta-analysis	127
A faecal microbiota signature with high specificity for pancreatic cancer	122
Lactobacillus rhamnosus GG induces cGAS/STING- dependent type I interferon and improves response to immune checkpoint blockade	121
Human milk oligosaccharide DSLNT and gut microbiome in preterm infants predicts necrotising enterocolitis	117
Reorganisation of faecal microbiota transplant services during the COVID-19 pandemic	116
Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort	116
Metabolic syndrome, metabolic comorbid conditions and risk of early-onset colorectal cancer	114
DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectives	113
Integrated analysis of the faecal metagenome and serum metabolome reveals the role of gut microbiome-associated metabolites in the detection of colorectal cancer and adenoma	113
Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach?	113
Host and gut microbial tryptophan metabolism and type 2 diabetes: an integrative analysis of host genetics, diet, gut microbiome and circulating metabolites in cohort studies	111
Artificial intelligence and colonoscopy experience: lessons from two randomised trials	110
Recent advances in clinical practice: epidemiology of autoimmune liver diseases	109
Residual SARS-CoV-2 viral antigens detected in GI and hepatic tissues from five recovered patients with COVID-19	109
Hepatitis B virus integrations promote local and distant oncogenic driver alterations in hepatocellular carcinoma	106
Liver injury is independently associated with adverse clinical outcomes in patients with COVID-19	105
Faecal immunochemical test is superior to symptoms in predicting pathology in patients with suspected colorectal cancer symptoms referred on a 2WW pathway: a diagnostic accuracy study	105
Bacteria-derived long chain fatty acid exhibits anti-inflammatory properties in colitis	104
Lactobacillus gallinarummodulates the gut microbiota and produces anti-cancer metabolites to protect against colorectal tumourigenesis	104
British Society of Gastroenterology guidelines for the management of iron deficiency anaemia in adults	103
Exosomes derived from Fusobacterium nucleatum-infected colorectal cancer cells facilitate tumour metastasis by selectively carrying miR-1246/92b-3p/27a-3p and CXCL16	103
Cigarette smoke promotes colorectal cancer through modulation of gut microbiota and related metabolites	103
Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification	102
Dysosmobacter welbionis is a newly isolated human commensal bacterium preventing diet-induced obesity and metabolic disorders in mice	102
Exploring prognostic indicators in the pathological images of hepatocellular carcinoma based on deep learning	101
Disrupted spermatogenesis in a metabolic syndrome model: the role of vitamin A metabolism in the gut–testis axis	101
Angiogenin maintains gut microbe homeostasis by balancing α-Proteobacteria and Lachnospiraceae	101
Current therapies and new developments in NASH	99
Cancer pharmacomicrobiomics: targeting microbiota to optimise cancer therapy outcomes	99
Long-term instability of the intestinal microbiome is associated with metabolic liver disease, low microbiota diversity, diabetes mellitus and impaired exocrine pancreatic func	98
Development and validation of a serum microRNA biomarker panel for detecting gastric cancer in a high-risk population	97

Microbiota tryptophan metabolism induces aryl hydrocarbon receptor activation and improves alcohol-induced liver injury	97
Global burden of disease: acute-on-chronic liver failure, a systematic review and meta-analysis	97
Helicobacter pylori infection has a detrimental impact on the efficacy of cancer immunotherapies	96
Sugar-sweetened beverage intake in adulthood and adolescence and risk of early-onset colorectal cancer among women	96
Inflammatory cell-derived CXCL3 promotes pancreatic cancer metastasis through a novel myofibroblast-hijacked cancer escape mechanism	95
Exosome-delivered CD44v6/C1QBP complex drives pancreatic cancer liver metastasis by promoting fibrotic liver microenvironment	94
Novel therapeutic targets for cholestatic and fatty liver disease	93
Blue poo: impact of gut transit time on the gut microbiome using a novel marker	91
Microbiota engraftment after faecal microbiota transplantation in obese subjects with type 2 diabetes: a 24-week, double-blind, randomised controlled trial	90
Gut microbiota composition is associated with SARS-CoV-2 vaccine immunogenicity and adverse events	88
Sphingomyelin synthase 1 mediates hepatocyte pyroptosis to trigger non-alcoholic steatohepatitis	88
Multitrait genetic association analysis identifies 50 new risk loci for gastro-oesophageal reflux, seven new loci for Barrett’s oesophagus and provides insights into clinical heterogeneity in reflux d	87
Targeting the gut-liver-immune axis to treat cirrhosis	86
Targeting cancer-associated fibroblast-secreted WNT2 restores dendritic cell-mediated antitumour immunity	86
Long-term yield of pancreatic cancer surveillance in high-risk individuals	86
Piecemeal cold snare polypectomy versus conventional endoscopic mucosal resection for large sessile serrated lesions: a retrospective comparison across two successive periods	86
Accuracy of a no-biopsy approach for the diagnosis of coeliac disease across different adult cohorts	82
Involvement of liver in COVID-19: systematic review and meta-analysis	81
MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis	80
Liquid biopsy in the clinical management of hepatocellular carcinoma	79
Cross-talk between the gut microbiota and monocyte-like macrophages mediates an inflammatory response to promote colitis-associated tumourigenesis	79
Advancing human gut microbiota research by considering gut transit time	79
ABC score: a new risk score that accurately predicts mortality in acute upper and lower gastrointestinal bleeding: an international multicentre study	77
High-affinity neoantigens correlate with better prognosis and trigger potent antihepatocellular carcinoma (HCC) activity by activating CD39+CD8+ T cells	77
25 years of anti-TNF treatment for inflammatory bowel disease: lessons from the past and a look to the future	77
Chinese Consensus Report on Family-BasedHelicobacter pyloriInfection Control and Management (2021 Edition)	76
Estimating the environmental impact of disposable endoscopic equipment and endoscopes	76
Faecal microbiota transplantation with anti-inflammatory diet (FMT-AID) followed by anti-inflammatory diet alone is effective in inducing and maintaining remission over 1 year in mild to moderate ulce	75
CXCR2 inhibition enables NASH-HCC immunotherapy	74
Endoscopy in patients on antiplatelet or anticoagulant therapy: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guideline update	74
Utilisation of artificial intelligence for the development of an EUS-convolutional neural network model trained to enhance the diagnosis of autoimmune pancreatitis	73
Combining ferroptosis induction with MDSC blockade renders primary tumours and metastases in liver sensitive to immune checkpoint blockade	73
Western-type diet influences mortality from necrotising pancreatitis and demonstrates a central role for butyrate	73
Single-cell RNA-seq analysis reveals BHLHE40-driven pro-tumour neutrophils with hyperactivated glycolysis in pancreatic tumour microenvironment	70
ATF4 activation promotes hepatic mitochondrial dysfunction by repressing NRF1–TFAM signalling in alcoholic steatohepatitis	69
Bidirectional brain–gut axis effects influence mood and prognosis in IBD: a systematic review and meta-analysis	69
Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis	68
Underdevelopment of the gut microbiota and bacteria species as non-invasive markers of prediction in children with autism spectrum disorder	68
Critical thresholds: key to unlocking the door to the prevention and specific treatments for acute pancreatitis	67
FSTL1 promotes liver fibrosis by reprogramming macrophage function through modulating the intracellular function of PKM2	67
Two microbiota subtypes identified in irritable bowel syndrome with distinct responses to the low FODMAP diet	67
Artificial intelligence-based pathology for gastrointestinal and hepatobiliary cancers	67
Gastric per-oral endoscopic myotomy (G-POEM) for refractory gastroparesis: results from an international prospective trial	67
First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn’s disease: an open-label multicentre randomised controlled trial	66
Association between proton pump inhibitor use and gastric cancer: a population-based cohort study using two different types of nationwide databases in Korea	65
Interplay between diet and gut microbiome, and circulating concentrations of trimethylamine N-oxide: findings from a longitudinal cohort of US men	64
Methionine deficiency facilitates antitumour immunity by altering m6A methylation of immune checkpoint transcripts	64
Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002–2033: the ITA.LI.CA database	64
RNA-binding protein RALY reprogrammes mitochondrial metabolism via mediating miRNA processing in colorectal cancer	64
Integrated metagenomic and metabolomic analysis reveals distinct gut-microbiome-derived phenotypes in early-onset colorectal cancer	63
British Society of Gastroenterology guidelines on the management of functional dyspepsia	63
Hepatic Krüppel-like factor 16 (KLF16) targets PPARα to improve steatohepatitis and insulin resistance	63
Long-term outcomes after endoscopic treatment for Barrett’s neoplasia with radiofrequency ablation ± endoscopic resection: results from the national Dutch database in a 10-year period	63
TREM-2 defends the liver against hepatocellular carcinoma through multifactorial protective mechanisms	62
Proton pump inhibitors and risk of gastric cancer: population-based cohort study	62
CDK1/2/5 inhibition overcomes IFNG-mediated adaptive immune resistance in pancreatic cancer	62
Mass eradication ofHelicobacter pylorito reduce gastric cancer incidence and mortality: a long-term cohort study on Matsu Islands	62
Human and preclinical studies of the host–gut microbiome co-metabolite hippurate as a marker and mediator of metabolic health	62
SARS-CoV-2 infection in acute pancreatitis increases disease severity and 30-day mortality: COVID PAN collaborative study	61
PBMC transcriptomics identifies immune-metabolism disorder during the development of HBV-ACLF	61
RIPK3 acts as a lipid metabolism regulator contributing to inflammation and carcinogenesis in non-alcoholic fatty liver disease	61
Dietary macronutrients and the gut microbiome: a precision nutrition approach to improve cardiometabolic health	61
Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size	61
Deconvolution of monocyte responses in inflammatory bowel disease reveals an IL-1 cytokine network that regulates IL-23 in genetic and acquired IL-10 resistance	59
Squalene epoxidase drives cancer cell proliferation and promotes gut dysbiosis to accelerate colorectal carcinogenesis	59
Equivalent performance of single-use and reusable duodenoscopes in a randomised trial	59
Recent advances in clinical practice: colorectal cancer chemoprevention in the average-risk population	58
Mapping the human gut mycobiome in middle-aged and elderly adults: multiomics insights and implications for host metabolic health	58
Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma	58
Niche-specific functional heterogeneity of intestinal resident macrophages	58
The tumour microenvironment shapes innate lymphoid cells in patients with hepatocellular carcinoma	58
Impairment of gut microbial biotin metabolism and host biotin status in severe obesity: effect of biotin and prebiotic supplementation on improved metabolism	58
Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis	57
Major GI bleeding in older persons using aspirin: incidence and risk factors in the ASPREE randomised controlled trial	57
Single-cell RNA sequencing reveals intrahepatic and peripheral immune characteristics related to disease phases in HBV-infected patients	56
Multiomics analysis reveals the presence of a microbiome in the gut of fetal lambs	56
Efficacy of biological therapies and small molecules in induction and maintenance of remission in luminal Crohn’s disease: systematic review and network meta-analysis	55
Liver function test abnormalities at hospital admission are associated with severe course of SARS-CoV-2 infection: a prospective cohort study	55
Organoids in gastrointestinal diseases: from experimental models to clinical translation	55
Altered faecal microbiome and metabolome in IgG4-related sclerosing cholangitis and primary sclerosing cholangitis	55

Blockade of interleukin 10 potentiates antitumour immune function in human colorectal cancer liver metastases	55
Targeting m6A reader YTHDF1 augments antitumour immunity and boosts anti-PD-1 efficacy in colorectal cancer	55
Severity of gastric intestinal metaplasia predicts the risk of gastric cancer: a prospective multicentre cohort study (GCEP)	55
Oncogenetic landscape of lymphomagenesis in coeliac disease	54
Prioritisation by FIT to mitigate the impact of delays in the 2-week wait colorectal cancer referral pathway during the COVID-19 pandemic: a UK modelling study	54
Topological analysis of hepatocellular carcinoma tumour microenvironment based on imaging mass cytometry reveals cellular neighbourhood regulated reversely by macrophages with different ontogeny	54
PICaSSO Histologic Remission Index (PHRI) in ulcerative colitis: development of a novel simplified histological score for monitoring mucosal healing and predicting clinical outcomes and its applicabil	54
Rewiring the altered tryptophan metabolism as a novel therapeutic strategy in inflammatory bowel diseases	53
Extracellular Vesicles from Pancreatic Cancer Stem Cells Lead an Intratumor Communication Network (EVNet) to fuel tumour progression	52
Long-term effectiveness of faecal immunochemical test screening for proximal and distal colorectal cancers	52
Endoscopic pyloromyotomy for the treatment of severe and refractory gastroparesis: a pilot, randomised, sham-controlled trial	51
Inflammatory bowel disease and Parkinson’s disease: common pathophysiological links	51
Interaction of bacterial metagenome and virome in patients with cirrhosis and hepatic encephalopathy	51
Clinical utility of 30% relative decline in MRI-PDFF in predicting fibrosis regression in non-alcoholic fatty liver disease	51
Role of serum HBV RNA and hepatitis B surface antigen levels in identifying Asian patients with chronic hepatitis B suitable for entecavir cessation	50
Amelioration of systemic inflammation in advanced chronic liver disease upon beta-blocker therapy translates into improved clinical outcomes	50
Normal values and regional differences in oesophageal impedance-pH metrics: a consensus analysis of impedance-pH studies from around the world	50
Integrative metabolomic characterisation identifies altered portal vein serum metabolome contributing to human hepatocellular carcinoma	50
Genomic evolution and diverse models of systemic metastases in colorectal cancer	49
COVID-19 and liver disease	49
Faecal immunochemical testing (FIT) in patients with signs or symptoms of suspected colorectal cancer (CRC): a joint guideline from the Association of Coloproctology of Great Britain and Ireland (ACPG	48
Synergistic targeting and resistance to PARP inhibition in DNA damage repair-deficient pancreatic cancer	48
Emerging treatment options for extraintestinal manifestations in IBD	48
Clinical and genomic characterisation of mismatch repair deficient pancreatic adenocarcinoma	47
Safety and efficacy of hydrothermal duodenal mucosal resurfacing in patients with type 2 diabetes: the randomised, double-blind, sham-controlled, multicentre REVITA-2 feasibility trial	47
Tumour-associated neutrophils secrete AGR2 to promote colorectal cancer metastasis via its receptor CD98hc–xCT	47
Multiregion whole-exome sequencing of intraductal papillary mucinous neoplasms reveals frequent somatic KLF4 mutations predominantly in low-grade regions	47
Regular use of proton pump inhibitors and risk of type 2 diabetes: results from three prospective cohort studies	46
Comparison of the Rome IV criteria with the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care	46
Effect of resolvins on sensitisation of TRPV1 and visceral hypersensitivity in IBS	46
From the origin of NASH to the future of metabolic fatty liver disease	46
Gut commensalParabacteroides distasonisalleviates inflammatory arthritis	46
Diet fuelling inflammatory bowel diseases: preclinical and clinical concepts	45
Recent advances in clinical practice: advances in cross-sectional imaging in inflammatory bowel disease	45
Autoimmune gastritis: long-term natural history in naïveHelicobacter pylori-negative patients	45
Large-scale, national, family-based epidemiological study onHelicobacter pyloriinfection in China: the time to change practice for related disease prevention	45
Proton pump inhibitor or famotidine use and severe COVID-19 disease: a propensity score-matched territory-wide study	45
Targeting pancreatic cancer by TAK-981: a SUMOylation inhibitor that activates the immune system and blocks cancer cell cycle progression in a preclinical model	44
Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications	44
Genetic architectures of proximal and distal colorectal cancer are partly distinct	44
Rapid resolution of COVID-19 after faecal microbiota transplantation	44
TOX defines the degree of CD8+ T cell dysfunction in distinct phases of chronic HBV infection	44
Global prevalence of Barrett’s oesophagus and oesophageal cancer in individuals with gastro-oesophageal reflux: a systematic review and meta-analysis	43
Thiopurine monotherapy is effective in ulcerative colitis but significantly less so in Crohn’s disease: long-term outcomes for 11 928 patients in the UK inflammatory bowel disease bioresource	43
Activation of the GPR35 pathway drives angiogenesis in the tumour microenvironment	43
Updates to the modern diagnosis of GERD: Lyon consensus 2.0	42
Prostaglandin E2 receptor PTGER4-expressing macrophages promote intestinal epithelial barrier regeneration upon inflammation	42
NAIL: an evolutionarily conserved lncRNA essential for licensing coordinated activation of p38 and NFκB in colitis	42
6α-hydroxylated bile acids mediate TGR5 signalling to improve glucose metabolism upon dietary fiber supplementation in mice	42
PI3K-driven HER2 expression is a potential therapeutic target in colorectal cancer stem cells	42
Chemotherapy-induced infiltration of neutrophils promotes pancreatic cancer metastasis via Gas6/AXL signalling axis	41
Non-compliance with colonoscopy after a positive faecal immunochemical test doubles the risk of dying from colorectal cancer	41
Placental growth factor promotes tumour desmoplasia and treatment resistance in intrahepatic cholangiocarcinoma	41
Risk factors for SARS-CoV-2 infection and course of COVID-19 disease in patients with IBD in the Veterans Affair Healthcare System	41
Impact of HBsAg and HBcrAg levels on phenotype and function of HBV-specific T cells in patients with chronic hepatitis B virus infection	41
Naproxen chemoprevention promotes immune activation in Lynch syndrome colorectal mucosa	41
Gestational diabetes is driven by microbiota-induced inflammation months before diagnosis	41
Two-dimensional shear wave elastography predicts survival in advanced chronic liver disease	41
A GATA6-centred gene regulatory network involving HNFs and ΔNp63 controls plasticity and immune escape in pancreatic cancer	41
Therapeutic shutdown of HBV transcripts promotes reappearance of the SMC5/6 complex and silencing of the viral genome in vivo	40
Non-alcoholic fatty liver disease and risk of new-onset heart failure: an updated meta-analysis of about 11 million individuals	40
Stool microRNA profiles reflect different dietary and gut microbiome patterns in healthy individuals	40
PD-L1 blockade liberates intrinsic antitumourigenic properties of glycolytic macrophages in hepatocellular carcinoma	40
Human gastric microbiota transplantation recapitulates premalignant lesions in germ-free mice	39
Serotonin is elevated in COVID-19-associated diarrhoea	39
Comparison of lumen-apposing metal stents versus double-pigtail plastic stents for infected necrotising pancreatitis	39
Exposure to corticosteroids in pregnancy is associated with adverse perinatal outcomes among infants of mothers with inflammatory bowel disease: results from the PIANO registry	39
Rescue of male fertility following faecal microbiota transplantation from alginate oligosaccharide-dosed mice	39
Whole exome HBV DNA integration is independent of the intrahepatic HBV reservoir in HBeAg-negative chronic hepatitis B	38
Development and initial psychometric validation of a patient-reported outcome measure for Crohn’s perianal fistula: the Crohn’s Anal Fistula Quality of Life (CAF-QoL) scale	38
Senolytic elimination of Cox2-expressing senescent cells inhibits the growth of premalignant pancreatic lesions	38
Proton pump inhibitors and the risk of severe COVID-19: a post-hoc analysis from the Korean nationwide cohort	38
Spatial profiling of gastric cancer patient-matched primary and locoregional metastases reveals principles of tumour dissemination	38
Faecal metabolome and its determinants in inflammatory bowel disease	37
Standalone performance of artificial intelligence for upper GI neoplasia: a meta-analysis	37
Multicentre, prospective, randomised study comparing the diagnostic yield of colon capsule endoscopy versus CT colonography in a screening population (the TOPAZ study)	37
Depression in individuals who subsequently develop inflammatory bowel disease: a population-based nested case–control study	37
Activated intestinal muscle cells promote preadipocyte migration: a novel mechanism for creeping fat formation in Crohn’s disease	37
What to do about the leaky gut	36
Health outcomes of 1000 children born to mothers with inflammatory bowel disease in their first 5 years of life	36
Dietary fibres and IBS: translating functional characteristics to clinical value in the era of personalised medicine	36
Over-the-scope-clips versus standard treatment in high-risk patients with acute non-variceal upper gastrointestinal bleeding: a randomised controlled trial (STING-2)	36
Microbial transmission, colonisation and succession: from pregnancy to infancy	36
Gut as viral reservoir: lessons from gut viromes, HIV and COVID-19	35
Computational modelling suggests that Barrett’s oesophagus may be the precursor of all oesophageal adenocarcinomas	35
Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis	35
Artificial intelligence in gastroenterology and hepatology: how to advance clinical practice while ensuring health equity	35
Blurring the picture in leaky gut research: how shortcomings of zonulin as a biomarker mislead the field of intestinal permeability	34
Next-generation sequencing of bile cell-free DNA for the early detection of patients with malignant biliary strictures	34
Irritable bowel syndrome: treatment based on pathophysiology and biomarkers	34
Protective and aggressive bacterial subsets and metabolites modify hepatobiliary inflammation and fibrosis in a murine model of PSC	34
Efficacy ofHelicobacter pylorieradication therapy for functional dyspepsia: updated systematic review and meta-analysis	34
Recovery of endoscopy services in the era of COVID-19: recommendations from an international Delphi consensus	34
International consensus to standardise histopathological scoring for small bowel strictures in Crohn’s disease	34
Periodontal disease, tooth loss, and risk of oesophageal and gastric adenocarcinoma: a prospective study	34